Heath Latham, MD
Pulmonary Disease · Kansas City, KSNPI 1639210123
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,330 of the $15,344 with a category attached, or 73.8%. Baxter Healthcare accounts for 73.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $6,478, 4.4 times the $1,478 reported in 2019. Among pulmonary disease clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $374.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$11K
- Vertex$1K
- Genentech USA, Inc.$1K
- Medtronic$947
- GSK$191
- La Jolla Pharmaceutical Company$162
- plus $360 from 5 others
Across 15 payments — averaging $10,556 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$131K
- Baxter Healthcare$27K
What the payments were for
- Consulting fees$11,33074%
- Speaking & faculty fees$1,0207%
- Travel & lodging$1,2098%
- Food & beverage$1,0637%
- Education$7235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 7 | $11,231 |
| Vertex | 9 | $1,434 |
| Genentech USA, Inc. | 1 | $1,020 |
| Medtronic | 3 | $947 |
| GSK | 13 | $191 |
| La Jolla Pharmaceutical Company | 2 | $162 |
| Pulmonx Corporation | 1 | $161 |
| Regeneron Healthcare Solutions, Inc. | 2 | $140 |
| AstraZeneca | 1 | $26 |
| Boehringer Ingelheim | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,344 in reported general payments places this provider in the 90th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $96,595 |
| NucalaMepolizumab | 26 | $92,806 |
| Dupixent PenDupilumab | 26 | $89,842 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 94 | $67,802 |
| XolairOmalizumab | 16 | $52,051 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $36,714 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $28,689 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $28,254 |
| Spiriva RespimatTiotropium Bromide | 19 | $12,641 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $8,155 |
| Arnuity ElliptaFluticasone Furoate | 32 | $6,759 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $4,566 |
| DuleraMometasone/Formoterol | 11 | $4,227 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,066 |
| Ventolin HfaAlbuterol Sulfate | 34 | $2,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $191 | $261,127281 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $26 | $75,956115 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $17 | $41,33058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Kansas City
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Kyle BrownbackKansas City$15K
- Michelle HomanKansas City$8K
- Aman KhanKansas City$5K
- Damien StevensKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.